Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Psychiatry Reports
Erschienen in: Current Psychiatry Reports 6/2012

01.12.2012 | Bipolar Disorders (MA Frye, Section Editor)

Obesity in Bipolar Disorder: An Overview

verfasst von: Susan L. McElroy, Paul E. Keck Jr

Erschienen in: Current Psychiatry Reports | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

Bipolar disorder (BD) is associated with obesity, overweight, and abdominal obesity, and BD individuals with obesity have a greater illness burden. Factors related to BD, its treatment, and the individual may all contribute to BD’s association with obesity. Management strategies for the obese BD patient include use of medications with better metabolic profiles, lifestyle interventions, and adjunctive pharmacotherapy for weight loss. Obesity-related psychiatric and medical comorbidities should also be assessed and managed. Bariatric surgery may be an option for carefully selected patients. Greater research into the theoretical underpinnings and clinical management of the BD-obesity connection is needed.
Literatur
1.
McElroy SL, Kotwal R, Malhotra S, et al. Are mood disorders and obesity related? A review for the mental health professional. J Clin Psychiatry. 2004;65:634–51.PubMedCrossRef
2.
McElroy SL. Obesity in patients with severe mental illness: Overview and management. J Clin Psychiatry. 2009;70 Suppl 3:12–21.PubMedCrossRef
3.
De Hert M, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10:52–77.
4.
Taylor VH, McIntyre RS, Remington G, et al. Beyond pharmacotherapy: Understanding the links between obesity and chronic mental illness. Can J Psychiatry. 2012;57:5–12.PubMed
5.
McIntyre RS, Alsuwaidan M, Goldstein BI, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders. Ann Clin Psychiatry. 2012;24:69–81.PubMed
6.
7.
National Institutes of Health. National Heart, Lung and Blood Institute: Clinical Guidelines on the Identification, Evaluation and Treatment of Overweight in Adults: The Evidence Report. National Institutes of Health, Bethesda, MD, 1998.
8.
9.
de Koning L, Merchant AT, Pogue J, et al. Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: Meta-regression analysis of prospective studies. Eur Heart J. 2007;28:850–6.PubMedCrossRef
10.
de Vegt F, Dekker JM, Jager A, et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. JAMA. 2001;285:2109–13.PubMedCrossRef
11.
Berrington de Gonzalez A, Hartge P, Cerhan JR, et al. Body-mass index and mortality among 146 million white adults. N Engl J Med. 2010;363:2211–9.PubMedCrossRef
12.
13.
Guize L, Pannier B, Thomas F, et al. Recent advances in metabolic syndrome and cardiovascular disease. Arch Cardiovasc Dis. 2008;101:577–83.PubMedCrossRef
14.
Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends in body-mass index since 1980: Systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011;377:557–67.PubMedCrossRef
15.
Ogden CL, Yanovski SZ, Carroll MD, et al. The epidemiology of obesity. Gastroenterology. 2007;132:2087–102.PubMedCrossRef
16.
Flegal KM, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA. 2012;307:491–7.PubMedCrossRef
17.
Sturm R. Increases in morbid obesity in the USA: 2000–2005. Public Health. 2007;121:492–6.PubMedCrossRef
18.
Walls HL, Magliano DJ, McNeil JJ, et al. Predictors of increasing waist circumference in an Australian population. Public Health Nutr. 2011;14:870–81.PubMedCrossRef
19.
•• McAllister EJ, Dhurandhar NV, Keith SW, et al. Ten putative contributors to the obesity epidemic. Crit Rev Food Sci Nutr. 2009;49:868–913. Excellent overview of potential factors contributing to the secular increase in obesity. PubMedCrossRef
20.
Keck PE, McElroy SL. Bipolar disorder, obesity, and pharmacotherapy-associated weight gain. J Clin Psychiatry. 2003;64:1426–35.PubMedCrossRef
21.
Sicras A, Rejas J, Navarro R, et al. Metabolic syndrome in bipolar disorder: A cross-sectional assessment of a Health Management Organization database. Bipolar Disord. 2008;10:607–16.PubMedCrossRef
22.
Weber NS, Fisher JA, Cowan DN, et al. Psychiatric and general medical conditions comorbid with bipolar disorder in the National Hospital Discharge Survey. Psychiatr Serv. 2011;62:1152–8.PubMedCrossRef
23.
Goldstein BI, Birmaher B, Axelson DA, et al. Preliminary findings regarding overweight and obesity in pediatric bipolar disorder. J Clin Psychiatry. 2008;69:1953–9.PubMedCrossRef
24.
Kim B, Kim SJ, Son JI, et al. Weight change in the acute treatment of bipolar I disorder: a naturalistic observational study of psychiatric inpatients. J Affect Disord. 2008;105:45–52.PubMedCrossRef
25.
Maina G, Salvi V, Vitalucci A, et al. Prevalence and correlates of overweight in drug-naive patients with bipolar disorder. J Affect Disord. 2008;110:149–55.PubMedCrossRef
26.
Alciati A, Gesuele F, Rizzi A, et al. Childhood parental loss and bipolar spectrum in obese bariatric surgery candidates. Int J Psychiatry Med. 2011;41:155–71.PubMedCrossRef
27.
McIntyre RS, Konarski JZ, Wilkins K, et al. Obesity in bipolar disorder and major depressive disorder: Results from a national community health survey on mental health and well-being. Can J Psychiatry. 2006;51:274–80.PubMed
28.
McIntyre RS, McElroy SL, Konarski JZ, et al. Substance use disorders and overweight/obesity in bipolar I disorder: Preliminary evidence for competing addictions. J Clin Psychiatry. 2007;68:1352–7.PubMedCrossRef
29.
• Simon GE, Von Korff M, Saunders K, et al. Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiatry. 2006;63:824–30. One of the first epidemiologic studies to demonstrate the co-variation between BD and obesity. PubMedCrossRef
30.
Goldstein BI, Liu SM, Zivkovic N, et al. The burden of obesity among adults with bipolar disorder in the United States. Bipolar Disord. 2011;13:387–95.PubMedCrossRef
31.
Petry NM, Barry D, Pietrzak RH, et al. Overweight and obesity are associated with psychiatric disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychosom Med. 2008;70:288–97.PubMedCrossRef
32.
Osby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58:844–50.PubMedCrossRef
33.
Brietzke E, Kapczinski F, Grassi-Oliveira R, et al. Insulin dysfunction and allostatic load in bipolar disorder. Expert Rev Neurother. 2011;11:1017–28.PubMedCrossRef
34.
Kilbourne AM, Cornelius JR, Han X, et al. Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disord. 2004;6:368–73.PubMedCrossRef
35.
Fagiolini A, Kupfer DJ, Rucci P, et al. Suicide attempts and ideation in patients with bipolar I disorder. J Clin Psychiatry. 2004;65:509–14.PubMedCrossRef
36.
Yim CY, Soczynska JK, Kennedy SH, et al. The effect of overweight/obesity on cognitive function in euthymic individuals with bipolar disorder. Eur Psychiatry. 2012;27:223–8.PubMedCrossRef
37.
• Fagiolini A, Kupfer DJ, Houck PR, et al. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry. 2003;160:112–7. The first prospective study to show an association between obesity and negative outcomes in BD. PubMedCrossRef
38.
Bond DJ, Kunz M, Torres IJ, et al. The association of weight gain with mood symptoms and functional outcomes following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). Bipolar Disord. 2010;12:616–26.PubMedCrossRef
39.
•• Goldstein BI, Kemp DE, Soczynska JK, et al. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: A systematic review of the literature. J Clin Psychiatry. 2009;70:1078–90. Excellent synthesis of the potential role inflammation plays in the relationship between BD and obesity. PubMedCrossRef
40.
Bond DJ, Lang DJ, Noronha MM, et al. The association of elevated body mass index with reduced brain volumes in first-episode mania. Biol Psychiatry. 2011;70:381–7.PubMedCrossRef
41.
Torrent C, Amann B, Sanchez-Moreno J, et al. Weight gain in bipolar disorder: Pharmacological treatment as a contributing factor. Acta Psychiatr Scand. 2008;118:4–18.PubMedCrossRef
42.
Lipkovich I, Citrome L, Perlis R, et al. Early predictors of substantial weight gain in bipolar patients treated with olanzapine. J Clin Psychopharmacol. 2006;26:316–20.PubMedCrossRef
43.
McElroy SL, Frye MA, Suppes T, et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry. 2002;63:207–13.PubMedCrossRef
44.
McElroy SL, Frye MA, Hellemann G, et al. Prevalence and correlates of eating disorders in 875 patients with bipolar disorder. J Affect Disord. 2011;128:191–8.PubMedCrossRef
45.
Barry D, Pietrzak RH, Petry NM. Gender differences in associations between body mass index and DSM-IV mood and anxiety disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Ann Epidemiol. 2008;18:458–66.PubMedCrossRef
46.
Elmslie JL, Mann JI, Silverstone JT, et al. Determinants of overweight and obesity in patients with bipolar disorder. J Clin Psychiatry. 2001;62:486–91.PubMedCrossRef
47.
Fleet-Michaliszyn SB, Soreca I, Otto AD, et al. A prospective observational study of obesity, body composition, and insulin resistance in 18 women with bipolar disorder and 17 matched control subjects. J Clin Psychiatry. 2008;69:1892–900.PubMedCrossRef
48.
Delgado-Rico E, Rio-Valle JS, Gonzalez-Jimenez E, et al. BMI predicts emotion-driven impulsivity and cognitive inflexibility in adolescents with excess weight. Obesity (Silver Spring). 2012;20:1604–10.CrossRef
49.
Fernandes BS, Gama CS, Cereser KM, et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res. 2011;45:995–1004.PubMedCrossRef
50.
Cordeira J, Rios M. Weighing in the role of BDNF in the central control of eating behavior. Mol Neurobiol. 2011;44:441–8.PubMedCrossRef
51.
Anand A, Barkay G, Dzemidzic M, et al. Striatal dopamine transporter availability in unmedicated bipolar disorder. Bipolar Disord. 2011;13:406–13.PubMedCrossRef
52.
Carlson PJ, Merlock MC, Suppes T. Adjunctive stimulant use in patients with bipolar disorder: treatment of residual depression and sedation. Bipolar Disord. 2004;6:416–20.PubMedCrossRef
53.
Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry. 2004;161:564–6.PubMedCrossRef
54.
Zarate Jr CA, Payne JL, Singh J, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry. 2004;56:54–60.PubMedCrossRef
55.
Frye MA, Grunze H, Suppes T, et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry. 2007;164:1242–9.PubMedCrossRef
56.
Calabrese JR, Ketter TA, Youakim JM, et al. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry. 2010;71:1363–70.PubMedCrossRef
57.
Finger BC, Dinan TG, Cryan JF. High-fat diet selectively protects against the effects of chronic social stress in the mouse. Neuroscience. 2011;192:351–60.PubMedCrossRef
58.
Yamada N, Katsuura G, Ochi Y, et al. Impaired CNS leptin action is implicated in depression associated with obesity. Endocrinology. 2011;152:2634–43.PubMedCrossRef
59.
Black DW, Goldstein RB, Mason EE, et al. Depression and other mental disorders in the relatives of morbidly obese patients. J Affect Disord. 1992;25:91–5.PubMedCrossRef
60.
Grucza RA, Krueger RF, Racette SB, et al. The emerging link between alcoholism risk and obesity in the United States. Arch Gen Psychiatry. 2010;67:1301–8.PubMedCrossRef
61.
Heber D, Carpenter CL. Addictive genes and the relationship to obesity and inflammation. Mol Neurobiol. 2011;44:160–5.PubMedCrossRef
62.
De Hert M, Cohen D, Bobes J, et al. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry. 2011;10:138–51.PubMed
63.
Ahmed AT, Blair TR, McIntyre RS. Surgical treatment of morbid obesity among patients with bipolar disorder: A research agenda. Adv Ther. 2011;28:389–400.PubMedCrossRef
64.
Mark AL. Dietary therapy for obesity: An emperor with no clothes. Hypertension. 2008;51:1426–34.PubMedCrossRef
65.
Rejeski WJ, Ip EH, Bertoni AG, et al. Lifestyle change and mobility in obese adults with type 2 diabetes. N Engl J Med. 2012;366:1209–17.PubMedCrossRef
66.
Alvarez-Jimenez M, Hetrick SE, Gonzalez-Blanch C, et al. Non-pharmacological management of antipsychotic-induced weight gain: Systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry. 2008;193:101–7.PubMedCrossRef
67.
Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev. 2007:CD005148.
68.
Gillhoff K, Gaab J, Emini L, et al. Effects of a multimodal lifestyle intervention on body mass index in patients with bipolar disorder: a randomized controlled trial. Prim Care Companion J Clin Psychiatry. 2010;12:pii.
69.
Sarris J, Mischoulon D, Schweitzer I. Adjunctive nutraceuticals with standard pharmacotherapies in bipolar disorder: A systematic review of clinical trials. Bipolar Disord. 2011;13:454–65.PubMedCrossRef
70.
Kwak SM, Myung SK, Lee YJ, et al. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: A meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med. 2012;172:686–94.
71.
Milaneschi Y, Bandinelli S, Penninx BW, et al. Depressive symptoms and inflammation increase in a prospective study of older adults: A protective effect of a healthy (Mediterranean-style) diet. Mol Psychiatry. 2011;16:589–90.PubMedCrossRef
72.
Elmslie JL, Porter RJ, Joyce PR, et al. Carnitine does not improve weight loss outcomes in valproate-treated bipolar patients consuming an energy-restricted, low-fat diet. Bipolar Disord. 2006;8:503–7.PubMedCrossRef
73.
Malik VS, Hu FB. Sweeteners and risk of obesity and type 2 diabetes: The role of sugar-sweetened beverages. Curr Diab Rep. 2012;12:195–203.
74.
Richardson CR, Faulkner G, McDevitt J, et al. Integrating physical activity into mental health services for persons with serious mental illness. Psychiatr Serv. 2005;56:324–31.PubMedCrossRef
75.
Alsuwaidan MT, Kucyi A, Law CW, et al. Exercise and bipolar disorder: A review of neurobiological mediators. Neuromolecular Med. 2009;11:328–36.PubMedCrossRef
76.
Sylvia LG, Ametrano RM, Nierenberg AA. Exercise treatment for bipolar disorder: potential mechanisms of action mediated through increased neurogenesis and decreased allostatic load. Psychother Psychosom. 2010;79:87–96.PubMedCrossRef
77.
Poulin MJ, Chaput JP, Simard V, et al. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme. Aust N Z J Psychiatry. 2007;41:980–9.PubMedCrossRef
78.
Wright K, Armstrong T, Taylor A, et al. ‘It’s a double edged sword’: A qualitative analysis of the experiences of exercise amongst people with bipolar disorder. J Affect Disord. 2012;136:634–42.PubMedCrossRef
79.
Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: A systematic review and meta-analysis. Neuropsychopharmacology. 2010;35:1520–30.PubMedCrossRef
80.
Agarwal SM, Behere RV, Venkatasubramanian G, et al. A case of successful treatment of comorbid obesity and polycystic ovarian disease with add-on metformin in bipolar disorder. Prim Care Companion CNS Disord. 2011;13:pii.
81.
McElroy SL, Guerdjikova AI, Mori N, et al. Pharmacolgical management of binge eating disorder: Current and emerging treatment options. Ther Clin Risk Manag. 2012;8:219–41.PubMedCrossRef
82.
Tchoukhine E, Takala P, Hakko H, et al. Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: A 16-week open-label extension phase and both phases of a randomized controlled trial. J Clin Psychiatry. 2011;72:326–30.PubMedCrossRef
83.
Ioannides-Demos LL, Piccenna L, McNeil JJ. Pharmacotherapies for obesity: Past, current, and future therapies. J Obes. 2011;2011:179674.PubMed
84.
Merideth CH. A single-center, double-blind, placebo-controlled evaluation of lamotrigine in the treatment of obesity in adults. J Clin Psychiatry. 2006;67:258–62.PubMedCrossRef
85.
Kushner SF, Khan A, Lane R, et al. Topiramate monotherapy in the management of acute mania: Results of four double-blind placebo-controlled trials. Bipolar Disord. 2006;8:15–27.PubMedCrossRef
86.
Roy Chengappa KN, Schwarzman LK, Hulihan JF, et al. Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: A randomized, placebo-controlled trial. J Clin Psychiatry. 2006;67:1698–706.PubMedCrossRef
87.
Roy Chengappa K, Kupfer DJ, Parepally H, et al. A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type. Bipolar Disord. 2007;9:609–17.PubMedCrossRef
88.
McIntyre RS, Mancini DA, McCann S, et al. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: A preliminary single-blind study. Bipolar Disord. 2002;4:207–13.PubMedCrossRef
89.
McElroy SL, Winstanley E, Mori N, et al. A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain. J Clin Psychopharmacol. 2012;32:165–72.PubMedCrossRef
90.
Bowden CL, Calabrese JR, Ketter TA, et al. Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder. Am J Psychiatry. 2006;163:1199–201.PubMedCrossRef
91.
Bray GA, Greenway FL. Pharmacological treatment of the overweight patient. Pharmacol Rev. 2007;59:151–84.PubMedCrossRef
92.
Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60:1079–88.PubMedCrossRef
93.
Cincotta AH, Meier AH. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care. 1996;19:667–70.PubMedCrossRef
94.
Henderson DC, Freudenreich O, Borba CP, et al. Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia. Schizophr Res. 2011;130:53–6.PubMedCrossRef
95.
Via MA, Chandra H, Araki T, et al. Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes. Diabetes Metab Syndr Obes. 2010;3:43–8.PubMedCrossRef
96.
Graham KA, Gu H, Lieberman JA, et al. Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. Am J Psychiatry. 2005;162:1744–6.PubMedCrossRef
97.
Deberdt W, Winokur A, Cavazzoni PA, et al. Amantadine for weight gain associated with olanzapine treatment. Eur Neuropsychopharmacol. 2005;15:13–21.PubMedCrossRef
98.
Semanscin-Doerr DA, Windover A, Ashton K, et al. Mood disorders in laparoscopic sleeve gastrectomy patients: Does it affect early weight loss? Surg Obes Relat Dis. 2010;6:191–6.PubMedCrossRef
99.
Steinmann WC, Suttmoeller K, Chitima-Matsiga R, et al. Bariatric surgery: 1-year weight loss outcomes in patients with bipolar and other psychiatric disorders. Obes Surg. 2011;21:1323–9.PubMedCrossRef
Metadaten
Titel
Obesity in Bipolar Disorder: An Overview
verfasst von
Susan L. McElroy
Paul E. Keck Jr
Publikationsdatum
01.12.2012
Verlag
Current Science Inc.
Erschienen in
Current Psychiatry Reports / Ausgabe 6/2012
Print ISSN: 1523-3812
Elektronische ISSN: 1535-1645
DOI
https://doi.org/10.1007/s11920-012-0313-8

Weitere Artikel der Ausgabe 6/2012

Current Psychiatry Reports 6/2012 Zur Ausgabe

Bipolar Disorders (MA Frye, Section Editor)

Integrating Bipolar Disorder Management in Primary Care

Hot Topic

Treatment of Childhood Sexual Abuse: An Updated Review

Mood Disorders (SM Strakowski, Section Editor)

Psychotic Depression—Beyond the Antidepressant/Antipsychotic Combination

Bipolar Disorders (MA Frye, Section Editor)

Biological Indicators of Suicide Risk in Youth With Mood Disorders: What Do We Know So Far?

Bipolar Disorders (MA Frye, Section Editor)

Staging and Neuroprogression in Bipolar Disorder

Mood Disorders (SM Strakowski, Section Editor)

Where in the Brain Is Depression?

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise